Stockreport

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast...

AstraZeneca PLC - American Depositary Shares  (AZN) 
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm Check Earnings Report
US:NYSE Investor Relations: astrazeneca.com/investor-relations.html
PDF Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca and Daiichi Sankyo’s ENHERTU in combination with pertuzumab reduced the risk of disease progres [Read more]